The management strategy for patients with myelodysplastic syndromes (MDS) has evolved from sole reliance on supportive measures to active treatment guided by disease risks. Recent progress in understanding the molecular pathogenesis of MDS has accelerated the discovery of new therapeutic targets, and consequently launched the development of several novel therapeutics that are currently in varied stages of clinical testing. One such agent is lenalidomide, which has shown remarkable effectiveness in the cytogenetically defined subset of MDS with the chromosome 5q31 deletion. The advent of new and effective targeted therapeutics may beneficially affect outcomes of an ever-increasing number of patients with MDS. This discussion summarizes the preliminary results of selected novel therapeutics.
Search Results
Aung Naing, Lubomir Sokol, and Alan F. List
David M. Thomas and Andrew J. Wagner
frequent coamplification of MDM2 and CDK4 in WDLPS/DDLPS is of particular interest because it presents an opportunity for combined use of targeted therapeutics. 31 Vascular Endothelial Growth Factor Receptor Pathway Vascular endothelial
David A. Reardon, Scott Turner, Katherine B. Peters, Annick Desjardins, Sridharan Gururangan, John H. Sampson, Roger E. McLendon, James E. Herndon II, Lee W. Jones, John P. Kirkpatrick, Allan H. Friedman, James J. Vredenburgh, Darell D. Bigner, and Henry S. Friedman
tempered by relatively modest improvements in overall survival, difficulties in assessing response after anti-VEGF therapeutics, and an inability to identify effective therapy after bevacizumab failure. Nonetheless, initial results have sparked a flurry of
Neel K. Gupta and Charalambos Andreadis
evaluated in larger frontline studies, and thus its utility remains unclear. 15 Striking a balance between efficacy and toxicity in this patient population is therefore challenging; however, the development of novel therapeutics and targeted agents has
Bryan J. Schneider
Small cell lung cancer remains one of the more frustrating malignancies for oncologists to treat. Although responses to initial platinum-based chemotherapy are high, most are not durable, and many patients are candidates for further palliative chemotherapy. Therapeutic options include reinduction or single-agent chemotherapy, depending on the duration of response to front-line treatment. Topotecan is the only approved agent for patients with relapsed disease. Several phase II studies have shown a modest benefit with other agents used today, although combination chemotherapy should be avoided because of increased toxicity. Palliative care should always be the focus, especially in patients with recurrent or chemorefractory small cell lung cancer and a poor performance status.
Sundar Jagannath
Presented by: Gregory J. Riely
Annual Conference, Dr. Riely, who is also a member of the NCCN Guidelines Panel for NSCLC, described which oncogenic molecular alterations can be targeted, and the efficacy and safety of their corresponding therapeutics according to line of treatment
Camille F. Ng, John Glaspy, Veronica R. Placencio-Hickok, Shant Thomassian, Jun Gong, Arsen Osipov, Andrew E. Hendifar, and Natalie Moshayedi
Despite advances in cancer therapeutics, pancreatic ductal adenocarcinoma (PDAC) remains among the deadliest malignancies, with a poor prognosis at time of diagnosis, reflecting a 5-year survival rate of approximately 10% across all stages and 2
Stephanie A. Morris, Dorothy Farrell, and Piotr Grodzinski
field of nanotechnology has emerged as an approach with the potential to produce novel diagnostics and therapeutics. At the nanoscale, materials are comparable in size to biological entities. They exhibit the ability to traverse the cellular environment
